Literature DB >> 24715588

Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.

Giovanni Luca Gravina1, Francesco Marampon, David Sherris, Francesca Vittorini, Ernesto Di Cesare, Vincenzo Tombolini, Andrea Lenzi, Emmanuele A Jannini, Claudio Festuccia.   

Abstract

BACKGROUND: P529, a Torc1/Torc2 inhibitor, has demonstrated its potential as a radiosensitizer. However the molecular mechanisms underlying this phenomenon still need to be elucidated. Aim of this study is to dissect molecular mechanisms regulating the radiosensitizing properties of P529 in a wide panel of prostate cancer models.
METHODS: Six tumor cell lines and xenograft models were used for in vitro and in vivo studies. Clonogenic survival, apoptotic, autophagic, and senescence assays were used to examine the effects of ionizing radiation (IR) alone and in combination with P529. CRM1, survivin, GSK-3β, and DNA-DSBs expression and modulation, upon P529 and RT, were monitored by western blot. In vivo treatment response upon P529, irradiation or combination of P529 with IR was monitored by tumor volume, time to progression (TTP), and immunohistochemical analysis.
RESULTS: P529 treatment induced significantly more apoptosis and DNA double-strand break (DSB) when combined with radiotherapy resulting in cellular radiosensitization and growth delay of irradiated tumor xenografts. Upon P529 treatment Rad51, DNA-PKcs, and Ku70 protein expression was downregulated, indicating delayed DNA double-strand damage repair. The radiosensitizing properties of P529 were partially linked to GSK-3β, cyclin-D1, and c-myc modulation with associated inhibition of CRM1-mediated nuclear export of survivin. Importantly, autophagy and tumor senescence were involved in the enhanced P529 radioresponse.
CONCLUSIONS: Impaired DNA double-strand damage repair, inhibition of CRM1-mediated nuclear export of survivin, modulation of cyclin-D1 and c-myc with associated pro-apoptotic and autophagic and senescent events explain the radiosensitizing properties of P529 in preclinical models of prostate cancer.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRM1; GSK-3β; P529; TORC1/TORC2; prostate cancer; radiotherapy; survivin

Mesh:

Substances:

Year:  2014        PMID: 24715588     DOI: 10.1002/pros.22804

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  The involvement of c-Myc in the DNA double-strand break repair via regulating radiation-induced phosphorylation of ATM and DNA-PKcs activity.

Authors:  Fengmei Cui; Rong Fan; Qiu Chen; Yongming He; Man Song; Zengfu Shang; Shimeng Zhang; Wei Zhu; Jianping Cao; Hua Guan; Ping-Kun Zhou
Journal:  Mol Cell Biochem       Date:  2015-06-07       Impact factor: 3.396

2.  Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.

Authors:  C Alberti
Journal:  G Chir       Date:  2015 May-Jun

3.  RAD51 regulates CHK1 stability via autophagy to promote cell growth in esophageal squamous carcinoma cells.

Authors:  Xinyi Zhu; Qiuhui Pan; Nan Huang; Jianchun Wu; Ni Zhen; Fenyong Sun; Zhi Li; Qingyuan Yang
Journal:  Tumour Biol       Date:  2016-10-14

Review 4.  Role of autophagy in regulating the radiosensitivity of tumor cells.

Authors:  Yong Xin; Fan Jiang; Chunsheng Yang; Qiuyue Yan; Wenwen Guo; Qian Huang; Longzhen Zhang; Guan Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-07       Impact factor: 4.553

Review 5.  Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.

Authors:  Hui Liu; Weimin Qiu; Tianyu Sun; Lei Wang; Chenxi Du; Yanyu Hu; Wenyuan Liu; Feng Feng; Yao Chen; Haopeng Sun
Journal:  Acta Pharm Sin B       Date:  2021-12-31       Impact factor: 14.903

6.  Mammalian Target of Rapamycin Inhibition With Rapamycin Mitigates Radiation-Induced Pulmonary Fibrosis in a Murine Model.

Authors:  Eun Joo Chung; Anastasia Sowers; Angela Thetford; Grace McKay-Corkum; Su I Chung; James B Mitchell; Deborah E Citrin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-28       Impact factor: 7.038

7.  Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Luca Scarsella; Alessandro Colapietro; Ana Jitariuc; Flora Vitale; Francesco Marampon; Enrico Ricevuto; Claudio Festuccia
Journal:  Tumour Biol       Date:  2015-07-29

8.  Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.

Authors:  Alonso Heredia; Nhut Le; Ronald B Gartenhaus; Edward Sausville; Sandra Medina-Moreno; Juan C Zapata; Charles Davis; Robert C Gallo; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 12.779

9.  KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Patrizia Sanita; Flora Vitale; Francesco Marampon; Luca Ventura; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Claudio Festuccia
Journal:  BMC Cancer       Date:  2015-12-01       Impact factor: 4.430

Review 10.  Epigenetic mechanisms underlying prostate cancer radioresistance.

Authors:  Catarina Macedo-Silva; Rosaria Benedetti; Fortunato Ciardiello; Salvatore Cappabianca; Carmen Jerónimo; Lucia Altucci
Journal:  Clin Epigenetics       Date:  2021-06-08       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.